New Veterinary Medicines Packaging Surveillance Scheme Set to Launch in 2026
Starting on 2 February 2026, the Veterinary Medicines Directorate (VMD) will implement a new surveillance system designed to oversee the packaging of veterinary medicines in the UK. This initiative aims to enhance regulatory monitoring while minimising the administrative load on the animal health sector.
Overview of the New Scheme
The VMD’s revised approach will involve bi-monthly evaluations of selected veterinary products currently available in the market. This assessment will encompass all elements of the packaging to ensure compliance with approved product information as dictated by established guidelines.
Assessment Process
Every three months, the VMD will identify a selection of products for packaging scrutiny. These will be sourced from wholesalers, and the evaluation framework aims to verify alignment with the Product Literature Standards. This proactive monitoring strategy is intended to balance regulatory oversight with efficiency.
Reporting Findings
Assessment results will be communicated to the respective Market Authorisation Holders (MAHs) within the three-month timeframe. Should any discrepancies be found, the VMD will provide recommendations for corrective action. Depending on the severity of the issue, these actions could range from minor updates to more formal amendments, or even categorising the issue as a product defect.
Changes to Mock-up Requirements
A significant aspect of the new regulatory landscape is the alteration in mock-up submission requirements. From 2 February 2026, the VMD will no longer necessitate mock-ups for certain variations and new marketing authorisations, streamlining the approval process for many products.
However, mock-ups will still be required in specific scenarios, including:
- Initial introductions of mock-ups prior to market release
- Joint assessments between the VMD and the Health Products Regulatory Authority (HPRA) for new marketing authorisations
- Evaluations of major design changes that are not related to the summary of product characteristics
When mock-ups are requested, submissions will be limited to the smallest commercially available pack size.
Impact on Ongoing Applications
The new guidelines will also influence ongoing G.I.18 variations and new marketing authorisation applications post-implementation date. The VMD will continue evaluations for mock-ups that have already been submitted, while newly initiated applications will proceed without mock-up requirements if they have not yet reached that assessment stage.
Background
This initiative reflects the VMD’s commitment to enhancing regulatory processes in the ever-evolving veterinary medicines market. By reassessing packaging oversight mechanisms, the VMD aims to foster a more efficient regulatory environment while ensuring compliance standards are met.
Source: official statements, news agencies, and public reports.
https://www.gov.uk/government/news/launch-of-new-veterinary-medicines-packaging-surveillance-scheme
